Skip to content
  • Kategorier
  • Seneste
  • Etiketter
  • Populære
  • Verden
  • Bruger
  • Grupper
Temaer
  • Light
  • Brite
  • Cerulean
  • Cosmo
  • Flatly
  • Journal
  • Litera
  • Lumen
  • Lux
  • Materia
  • Minty
  • Morph
  • Pulse
  • Sandstone
  • Simplex
  • Sketchy
  • Spacelab
  • United
  • Yeti
  • Zephyr
  • Dark
  • Cyborg
  • Darkly
  • Quartz
  • Slate
  • Solar
  • Superhero
  • Vapor

  • Default (No Skin)
  • No Skin
Kollaps
  1. Debatforum
  2. Kategorier
  3. Genmab
  4. Genmab — Juni 2023

Genmab — Juni 2023

Planlagt Fastgjort Låst Flyttet Genmab
702 Indlæg 1 Posters 0 Visninger
  • Ældste til nyeste
  • Nyeste til ældste
  • Most Votes
Svar
  • Svar som emne
Login for at svare
Denne tråd er blevet slettet. Kun brugere med emne behandlings privilegier kan se den.
  • B Offline
    B Offline
    bibob
    wrote on sidst redigeret af
    #96

    Sorry. Havde ikke set E L link 21.07 😉

    1 Reply Last reply
    0
    • SolsenS Offline
      SolsenS Offline
      Solsen
      wrote on sidst redigeret af
      #97

      https://www.bt.dk/udland/nyt-studie-overrasker-pille-halverer-risikoen-for-at-doe-af-lungekraeft Osimertinib vækker opsigt. Amivantamab går efter det marked (Tagrisso) i kombi med Lazertinib.

      1 Reply Last reply
      0
      • P Offline
        P Offline
        Pensionisten
        wrote on sidst redigeret af
        #98

        Fireside Goldman Sachs - desværre ikke Jan, der deltager (link)

        1 Reply Last reply
        0
        • P Offline
          P Offline
          Pensionisten
          wrote on sidst redigeret af
          #99

          https://ir.genmab.com/genmab-news#content

          1 Reply Last reply
          0
          • E Offline
            E Offline
            E_L
            wrote on sidst redigeret af
            #100

            Wainwright analyst Ram Selvaraju reiterated a Buy rating on Genmab (GMAB – Research Report) today and set a price target of $51.00.

            1 Reply Last reply
            0
            • K Offline
              K Offline
              Klarussen
              wrote on sidst redigeret af
              #101

              Lyder meget rimeligt

              1 Reply Last reply
              0
              • B Offline
                B Offline
                bikube
                wrote on sidst redigeret af
                #102

                Den 22. maj hævede han fra 47 til 51. Det svarer til lidt over 3500 i DK.

                1 Reply Last reply
                0
                • SolsenS Offline
                  SolsenS Offline
                  Solsen
                  wrote on sidst redigeret af
                  #103

                  Lidt om Car-T https://endpts.com/new-car-t-data-look-spectacular-but-how-many-patients-will-take-it-and-when-asco23/

                  1 Reply Last reply
                  0
                  • E Offline
                    E Offline
                    E_L
                    wrote on sidst redigeret af
                    #104

                    longer term results of patients with DLBCL treated with epcoritamab+R-CHOP. The latest results support the preliminary data and this treatment induces high CMR rates with a manageable safety profile https://twitter.com/lymphomahub/status/1666142892270682128

                    1 Reply Last reply
                    0
                    • BulderB Offline
                      BulderB Offline
                      Bulder
                      wrote on sidst redigeret af
                      #105

                      Dansk begejstring over FDA-godkendelse af epcoritamab: Det er et stort fremskridt

                      1 Reply Last reply
                      0
                      • BulderB Offline
                        BulderB Offline
                        Bulder
                        wrote on sidst redigeret af
                        #106

                        Link Preview Image
                        Dansk begejstring over FDA-godkendelse af epcoritamab: Det er et stort fremskridt

                        De amerikanske lægemiddelmyndigheder FDA har godkendt det bispecifikke antistof epcoritamab til behandling af patienter med relaps eller refraktært (r/r) storce

                        favicon

                        (haematologisktidsskrift.dk)

                        1 Reply Last reply
                        0
                        • BulderB Offline
                          BulderB Offline
                          Bulder
                          wrote on sidst redigeret af
                          #107

                          God og grundig artikel, der belyser “styrkeforholdet” epco/glofi/car-t.

                          1 Reply Last reply
                          0
                          • P Offline
                            P Offline
                            Pensionisten
                            wrote on sidst redigeret af
                            #108

                            Tak for den gode artikel, @Bulder. Den var til at forstå - selv for mig! Og det siger ikke så lidt 😉

                            1 Reply Last reply
                            0
                            • E Offline
                              E Offline
                              E_L
                              wrote on sidst redigeret af
                              #109

                              Epcoritamab Plus Rituximab/Lenalidomide Produces Responses in High-risk R/R Follicular Lymphoma https://www.onclive.com/view/epcoritamab-plus-rituximab-lenalidomide-produces-responses-in-high-risk-r-r-follicular-lymphoma (this was the oral presentation)

                              1 Reply Last reply
                              0
                              • E Offline
                                E Offline
                                E_L
                                wrote on sidst redigeret af
                                #110

                                Epcoritamab + R2 regimen and responses in high-risk follicular lymphoma, regardless of POD24 status. https://ascopubs.org/doi/abs/10.1200/JCO.2023.41.16_suppl.7506?af=R

                                1 Reply Last reply
                                0
                                • E Offline
                                  E Offline
                                  E_L
                                  wrote on sidst redigeret af
                                  #111

                                  so the first article is the new/later cutoff date of January 31, 2023; results very similar

                                  1 Reply Last reply
                                  0
                                  • E Offline
                                    E Offline
                                    E_L
                                    wrote on sidst redigeret af
                                    #112

                                    104 efficacy evaluable patients treated with epcoritamab at 48 mg plus R2, the overall response rate (ORR) was 98% (median follow-up, 11.4 months). The complete metabolic response (CMR) was
                                    87%

                                    1 Reply Last reply
                                    0
                                    • E Offline
                                      E Offline
                                      E_L
                                      wrote on sidst redigeret af
                                      #113

                                      (versus the the immediate prior therapy they progressed on,
                                      85% and 58% respectively)

                                      1 Reply Last reply
                                      0
                                      • E Offline
                                        E Offline
                                        E_L
                                        wrote on sidst redigeret af
                                        #114

                                        easier article maybe - Positive Responses Seen in Follicular Lymphoma When Epcoritamab Is Added to Rituximab and Lenalidomide https://dailynews.ascopubs.org/do/positive-responses-seen-follicular-lymphoma-epcoritamab-added-rituximab-and

                                        1 Reply Last reply
                                        0
                                        • BulderB Offline
                                          BulderB Offline
                                          Bulder
                                          wrote on sidst redigeret af
                                          #115

                                          As far as I remember Genmab was planning to file epco for approval in FL this year. But I don’t remember if it was RR or 1L. Do you?

                                          1 Reply Last reply
                                          0

                                          Hello! It looks like you're interested in this conversation, but you don't have an account yet.

                                          Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.

                                          With your input, this post could be even better 💗

                                          Tilmeld Log ind
                                          Svar
                                          • Svar som emne
                                          Login for at svare
                                          • Ældste til nyeste
                                          • Nyeste til ældste
                                          • Most Votes


                                          • Log ind

                                          • Har du ikke en konto? Tilmeld

                                          • Login or register to search.
                                          Powered by NodeBB Contributors
                                          • First post
                                            Last post
                                          0
                                          • Kategorier
                                          • Seneste
                                          • Etiketter
                                          • Populære
                                          • Verden
                                          • Bruger
                                          • Grupper